Acquiring Company
SNBL
Acquired Company
Satsuma Pharmaceuticals, Inc.
Japan
San FranciscoBiotechnologyHealthcareHealth CarePharmaceuticalBiopharmaDescription
Satsuma Pharmaceuticals, Inc. (“Satsuma”) (Nasdaq: STSA) today announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. (TSE: 2395, “SNBL”) for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right (“CVR”) of up to $5.77 per share. The CVR is payable pursuant to the future sale, license, or any other monetization events related to STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, (subject to certain terms and conditions, as set forth in more detail below). Satsuma submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in March 2023 for STS101, which incorporates nasal powder formulation and delivery device technologies developed by SNBL and exclusively licensed by Satsuma.
Quick answer
SNBL is acquiring Satsuma Pharmaceuticals, Inc., announced April 16, 2023. SNBL is based in Japan.
- Who acquired Satsuma Pharmaceuticals, Inc?
- SNBL agreed to acquire Satsuma Pharmaceuticals, Inc. on April 16, 2023.
- How much did SNBL pay for Satsuma Pharmaceuticals, Inc?
- The deal value was not disclosed.
- What does SNBL do?
- 新日本科学（SNBL）は1957年に創業した、わが国初の医薬品開発受託研究機関（CRO）です。
- Where are SNBL and Satsuma Pharmaceuticals, Inc. based?
- SNBL is based in Japan. Satsuma Pharmaceuticals, Inc. is based in San Francisco, California, United States.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Abiogen Pharma Completes The Acquisition Of Effrx (May 29, 2023)
- Sumitovant Biopharma Completes Acquisition Of Myovant Sciences (March 10, 2023)
- Sobi To Acquire Cti Biopharma (May 10, 2023)
- Genesis Drug Discovery & Development (Gd3), A Member Of Genesis Global Group, Acquires Jss Medical Research To Expand Its Clinical Services Portfolio (May 10, 2023)
- Shockwave Medical Completes Acquisition Of Neovasc (April 11, 2023)
- Medtronic To Acquire Wearable Insulin Patch Maker Eoflow (May 25, 2023)
Who to call at SNBL, and when
When SNBL changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day SNBL raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at SNBL, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at SNBL. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment SNBL makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Satsuma Pharmaceuticals, Inc.?
Satsuma Pharmaceuticals, Inc. was acquired by SNBL, based in Japan. The deal was reported on April 16, 2023. 新日本科学（SNBL）は1957年に創業した、わが国初の医薬品開発受託研究機関（CRO）です。 SNBL is privately held.
When did SNBL acquire Satsuma Pharmaceuticals, Inc.?
SNBL's acquisition of Satsuma Pharmaceuticals, Inc. was reported on April 16, 2023. Satsuma Pharmaceuticals, Inc. (“Satsuma”) (Nasdaq: STSA) today announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Satsuma Pharmaceuticals, Inc. do?
Developing best-in-class products to address the unmet needs of migraine sufferers It is privately held, operating in Biotechnology, and is based in San Francisco.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.